Patents by Inventor Kevin Fitzgerald

Kevin Fitzgerald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for inhibiting expression of the PCSK9 gene
    Patent number: 8809292
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: August 19, 2014
    Assignee: Alnylam Pharmaceuticals, Inc
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor E. Kotelianski
  • Compositions and methods for inhibiting expression of XBP-1 gene
    Patent number: 8765932
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting X-Box Protein 1 (XBP-1), and methods of using the dsRNA to inhibit expression of XBP-1.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: July 1, 2014
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, Gregory Hinkle
  • ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20140179768
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
    Type: Application
    Filed: December 18, 2013
    Publication date: June 26, 2014
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Brian Bettencourt, William Querbes, Kevin Fitzgerald, Maria Frank-Kamenetsky, Stuart Milstein, Svetlana Shulga Morskaya
  • LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE
    Publication number: 20140121263
    Abstract: This invention relates to composition and methods using lipid formulated siRNA targeted to a PCSK9 gene.
    Type: Application
    Filed: October 18, 2013
    Publication date: May 1, 2014
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, Gregory Hinkle, Akin Akinc, Stuart Milstein
  • Compositions and Methods for Inhibition of Expression of Apolipoprotein C-III (APOC3) Genes
    Publication number: 20140113957
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) targeting an APOC3 gene, and methods of using the dsRNA to inhibit expression of APOC3.
    Type: Application
    Filed: June 21, 2012
    Publication date: April 24, 2014
    Inventors: Brian Bettencourt, Kevin Fitzgerald, Stuart Milstein, Martin Maier, Klaus Charisse, Rajeev Kallanthottathil, Satyanarayana Kuchimanchi, Muthiah Manoharan, Tuyen Nguyen
  • In vitro peptide expression library
    Patent number: 8679781
    Abstract: The invention provides a method for making in vitro peptide expression libraries, and for the isolation of nucleotide sequences encoding peptides of interest, wherein the peptides or proteins are specifically associated with the DNA encoding them through non-covalent protein:DNA binding. The method describes ways of making the library itself, DNA molecules encoding the library and uses of the expression library.
    Type: Grant
    Filed: October 21, 2010
    Date of Patent: March 25, 2014
    Assignee: Isogenica Limited
    Inventors: Duncan McGregor, Richard Odegrip, Kevin Fitzgerald, Rosemarie Hederer, Bill Eldridge, Chris Ullman, Philip Kuhlman, David Coomber
  • Compositions And Methods For Inhibiting Expression Of The PCSK9 Gene
    Publication number: 20130331430
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene.
    Type: Application
    Filed: May 15, 2012
    Publication date: December 12, 2013
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor E. Kotelianski
  • Lipid formulated dsRNA targeting the PCSK9 gene
    Patent number: 8598139
    Abstract: This invention relates to composition and methods using lipid formulated siRNA targeted to a PCSK9 gene.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: December 3, 2013
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, Gregory Hinkle, Akin Akinc, Stuart Milstein
  • MODIFIED iRNA AGENTS
    Publication number: 20130317080
    Abstract: The present invention provides effective motifs for RNA agents conjugated to at least one ligand, which are advantageous for the in vivo delivery of iRNA duplex agents. Additionally, the present invention provides methods of making these compositions, as well as methods of introducing these iRNA duplex agents into cells using these compositions, e.g., for the treatment of various disease conditions.
    Type: Application
    Filed: September 14, 2011
    Publication date: November 28, 2013
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Kallanthottathil G. Rajeev, Tracy Zimmermann, Muthiah Manoharan, Martin Maier, Kevin Fitzgerald
  • Compositions and Methods for Inhibition of PCSK9 Genes
    Publication number: 20130289094
    Abstract: The invention relates to siRNAs targeting a PCSK9 gene, and methods of using siRNAs to inhibit expression of PC-SK9 and to treat PCSK9 related disorders, e.g., hyperlipidemia.
    Type: Application
    Filed: October 31, 2011
    Publication date: October 31, 2013
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Gregory Hinkle, Maria Frank-Kamenetsky, Kevin Fitzgerald
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
    Publication number: 20130281511
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 24, 2013
    Inventors: Brian Bettencourt, Kevin Fitzgerald, William Querbes, Robert J. Desnick, Makiko Yasuda
  • Membrane-translocating peptides
    Patent number: 8557744
    Abstract: A method is selects membrane-translocating peptides (MTPs) from a peptide display library that are capable of crossing or penetrating a lipid membrane. A plurality of nucleic acid constructs that encode displayed peptides are expressed, resulting in the formation of a plurality of nucleic acid-peptide complexes, each complex comprising at least one displayed peptide associated with the corresponding nucleic acid construct encoding the displayed peptide; the complexes are exposed to a population of membrane-encapsulated compartments, allowing a translocating reaction to occur; complexes that remain unassociated with the membrane are removed; optionally complexes that are associated with the membrane are removed; and internalized nucleic acid-peptide complexes are recovered. The membrane-encapsulated compartments may be artificial vesicles such as liposomes, or populations of one or more cell types.
    Type: Grant
    Filed: July 24, 2006
    Date of Patent: October 15, 2013
    Assignee: Isogenica Ltd.
    Inventors: David Coomber, Kevin Fitzgerald, Duncan McGregor, Chris Ullman, Tomas Leanderson
  • Dual Targeting siRNA Agents
    Publication number: 20130184324
    Abstract: The invention relates to dual targeting siRNA agents targeting a PCSK9 gene and a second gene, and methods of using dual targeting siRNA agents to inhibit expression of PCSK.9 and to treat PCSK.9 related disorders, e.g., hyperlipidemia.
    Type: Application
    Filed: September 22, 2010
    Publication date: July 18, 2013
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, Maria Frank-Kamenetsky, Klaus Charisse
  • Wind noise classifier
    Patent number: 8457320
    Abstract: A special purpose machine measures and modulates communication signals that are parsed into frames. Frames of signals modulated and measured to have certain qualities are deemed to be the result of wind noise. Frames of wind noise are cancelled from further use within a communication system.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: June 4, 2013
    Inventors: Alon Konchitsky, Alberto D Berstein, Sandeep Kulakcherla, William Martin Ribble, Kevin Fitzgerald, Don Seferovich
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MYLIP/IDOL GENE
    Publication number: 20130123332
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Mylip/Idol gene, and methods of using such dsRNA compositions to inhibit expression of Mylip/Idol.
    Type: Application
    Filed: January 25, 2011
    Publication date: May 16, 2013
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Brian Bettencourt, Kevin Fitzgerald, Muthiah Manoharan
  • Method for wind noise reduction
    Patent number: 8433564
    Abstract: A noisy signal is picked up by a microphone, digitized by an Analog to Digital Converter and fed to a processor for analysis and wind noise reduction. Most of noise reduction methods are based on the assumption that the interfering noise is stationary or slowly varying compared with speech. This assumption allows “learning” the characteristics of the noise between speech pauses and, based on a noise estimate, to build different filters that reduce the noise. In the case of wind noise this basic assumption is not valid. Wind noise is highly non-stationary, its power and spectral characteristics vary greatly. Because wind noise is not stationary, regular noise reduction methods cannot be used to reduce wind noise. For reducing wind noise effects in a device, the presence of wind should be detected reliably and then a novel approach presented here must be applied to eliminate the wind noise.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: April 30, 2013
    Inventors: Alon Konchitsky, Alberto D Berstein, Sandeep Kulakcherla, William Martin Ribble, Kevin Fitzgerald, Don Seferovich
  • LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE
    Publication number: 20130035371
    Abstract: This invention relates to composition and methods using lipid formulated siRNA targeted to a PCSK9 gene.
    Type: Application
    Filed: August 7, 2012
    Publication date: February 7, 2013
    Inventors: Kevin Fitzgerald, Gregory Hinkle, Akin Akinc, Stuart Milstein
  • Compositions and Methods for Inhibiting Expression of XBP-1 Gene
    Publication number: 20130023580
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting X-Box Protein 1 (XBP-1), and methods of using the dsRNA to inhibit expression of XBP-1.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 24, 2013
    Inventors: Kevin Fitzgerald, Gregory Hinkle
  • Compositions and methods for inhibiting expression of XBP-1 gene
    Patent number: 8344126
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting X-Box Protein 1 (XBP-1), and methods of using the dsRNA to inhibit expression of XBP-1.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: January 1, 2013
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, Gregory Hinkle
  • Speech and music discriminator for multi-media application
    Patent number: 8340964
    Abstract: The present invention relates to means and methods of classifying speech and music signals in voice communication systems, devices, telephones, and methods, and more specifically, to systems, devices, and methods that automate control when either speech or music is detected over communication links. The present invention provides a novel system and method for monitoring the audio signal, analyze selected audio signal components, compare the results of analysis with a pre-determined threshold value, and classify the audio signal either as speech or music.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: December 25, 2012
    Inventors: Alon Konchitsky, Alberto D Berstein, Sandeep Kulakcherla, William Martin Ribble, Kevin Fitzgerald, Don Seferovich